newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid